1. Field of the Invention
The present invention relates to radiation beam therapy systems, and more particularly to a radiation treatment system with a patient positioner. The present invention relates to radiation beam therapy systems, and more particularly to a modular patient support system. The present invention relates to radiation beam therapy systems, and more particularly to a patient pod with tapered edge configurations that reduce edge effects associated with abrupt changes in the water equivalency in the radiation beam path.
2. Description of the Related Art
Radiation therapy systems are known and used to provide treatment to patients suffering a wide variety of conditions. Radiation therapy is typically used to kill or inhibit the growth of undesired tissue, such as cancerous tissue. A determined quantity of high-energy electromagnetic radiation and/or high-energy particles are directed into the undesired tissue with the goal of damaging the undesired tissue while reducing unintentional damage to desired or healthy tissue through which the radiation passes on its path to the undesired tissue.
Proton therapy has emerged as a particularly efficacious treatment for a variety of conditions. In proton therapy, positively charged proton subatomic particles are accelerated, collimated into a tightly focused beam, and directed towards a designated target region within the patient. Protons exhibit less lateral dispersion upon impact with patient tissue than electromagnetic radiation or low mass electron charged particles and can thus be more precisely aimed and delivered along a beam axis. Also, upon impact with patient tissue, protons exhibit a characteristic Bragg peak wherein a significant portion of the kinetic energy of the accelerated mass is deposited within a relatively narrow penetration depth within the patient. This offers the significant advantage of reducing delivery of energy from the accelerated proton particles to healthy tissue interposed between the target region and the delivery nozzle of a proton therapy machine as well as to “downrange” tissue lying beyond the designated target region. Depending on the indications for a particular patient and their condition, delivery of the therapeutic proton beam may preferably take place from a plurality of directions in multiple treatment fractions to maintain a total dose delivered to the target region while reducing collateral exposure of interposed desired/healthy tissue.
U.S. Pat. No. 4,870,287, issued Sep. 26, 1989, assigned to the Loma Linda University Medical Center, titled MULTI-STATION PROTON BEAM THERAPY SYSTEM, describes and illustrates a radiation beam therapy system. The system described therein includes several different treatment stations, each including a gantry for supporting and rotating a radiation beam transport and delivery system on an axis of rotation around a stationary patient to deliver a treatment beam to a predetermined target isocenter within the patient from several different angles.
With many radiation treatment systems and protocols, a unique treatment plan is first developed for each cancer patient. For example, in the development of a treatment plan, such as, for example, proton radiation treatment, the patient is generally positioned on a support table or support structure and the internal anatomy of the patient's body scanned with an imaging technique, such as, for example, computed tomography (CT Scan). Images produced by the imaging device are analyzed to precisely locate the cancer sites defining the targets for the radiation beams. In many cases, physicians develop a radiation treatment plan calling for a number of different patient treatment sessions with radiation beams of different magnitudes, durations and angles of direction.
Given the high number of cancer patients who could benefit from radiation treatment and the relatively few number of sophisticated radiation (e.g., proton) treatment facilities and systems available in the world, there is a need for radiation treatment providers to achieve greater patient throughput at their existing facilities. As such, there is a need for patient support and positioning systems that utilize automated or robotic patient positioning devices, and thereby provide radiation treatment providers with the ability to achieve increased patient throughput.
For each treatment session, it is important that the patient be supported in the exact same position as during the preliminary imaging or scanning session utilized in the development of the treatment plan (i.e., the original position). Accordingly, there is a need for a patient positioning and repositioning support system for fixedly securing a patient in an original position during radiation treatment and for repositioning the patient in the same original position during any subsequent radiation treatment sessions. For certain applications that involve irradiating different portions of a patient's anatomy from several different angles, it is desirable for the patient positioning and repositioning support to fixedly secure the patient.
The radiation treatment protocol for any given patient can depend on a number of factors, including, for example: the size and physical characteristics of the patient; the type, size, and location of the tumor(s) being irradiated; and the aggressiveness of the treatment protocol. As such, there is a need for a modular patient support system that can be easily adjusted to accommodate a large number of treatment protocols.
For certain treatment protocols it is necessary to direct the radiation beam at angles that traverse at least one lateral edge of the patient pod. Accordingly, there is a need for pod edge configuration that reduces discontinuities in the strength or intensity of radiation beams that pass through or near a pod lateral edge.
In accordance with one embodiment described herein, there is provided a radiation treatment system for delivering prescribed doses of radiation to a targeted site within a cancer patient and for increasing patient throughput levels. The treatment system includes: a patient treatment station; a gantry, a radiation beam source; a nozzle; a modular patient support system; a patient positioner; and a control system.
In one embodiment, the radiation beam source includes a source of protons and an accelerator for accelerating protons as a beam.
In accordance with one embodiment described herein, there is provided a modular patient support system for efficiently securing a cancer patient in a fixed position during radiation treatment. The support system includes a modular patient pod.
In accordance with one embodiment described herein, there is provided a modular patient pod for providing cantilevered support of a cancer patient undergoing radiation treatment. The pod includes: a longitudinally-extending support shell; a proximal extension track; a distal extension track; and a positioner-pod connector.
In one embodiment, the support shell is made from a treat-through material, such as, for example, carbon fiber.
In one embodiment, a distal pod attachment is engaged with the distal extension track. In another embodiment, a proximal pod attachment is engaged with the proximal extension track.
In accordance with one embodiment described herein, there is provided a modular patient pod that is configured to reduce any edge effects. The pod includes a support shell having a first lateral edge and a second lateral edge.
In one embodiment, the first lateral edge includes a first tapered edge and a first rail made from a first low-density material, such as, for example, epoxy with microspheres. In another embodiment, the second lateral edge includes a second tapered edge and a second rail made from a second low-density material.
In accordance with one embodiment described herein, there is provided a radiation treatment system with a patient positioner.
Reference will now be made to the drawings wherein like reference designators refer to like parts throughout.
In one embodiment, the radiation therapy system 100 is designed to deliver therapeutic doses of proton beams to a target area within the patient. Additional details on the structure and operation of the such a system 100 can be found in U.S. Pat. No. 4,870,287, titled MULTI-STATION PROTON BEAM THERAPY SYSTEM, which is incorporated herein in its entirety by reference. In another embodiment, the system 100 is designed to deliver any other clinically suitable form of radiation known in the art, such as, for example, x-rays, gamma rays, hadrons, neutrons, etc.
The radiation therapy system 100 typically includes a patient treatment station and a gantry 102 which includes a generally hemispherical or frustoconical support frame for attachment and support of other components of the radiation therapy system 100. Additional details on the structure and operation of the gantry 102 can be found in U.S. Pat. No. 4,917,344 and U.S. Pat. No. 5,039,057, both titled ROLLER-SUPPORTED, MODULAR, ISOCENTRIC GENTRY AND METHOD OF ASSEMBLY, both of which are incorporated herein in their entirety by reference.
With continued reference to
With continued reference to
The system 100 also comprises a patient positioner 114 and a patient pod 200 which is attached to positioner-pod connector 234 at the distal, working end 116 of the patient positioner 114. The patient positioner 114 is adapted to, upon receipt of appropriate movement commands, position the patient pod 200 in multiple translational and rotational axes and preferably is capable of positioning the patient pod 200 in three orthogonal translational (i.e., the longitudinal, vertical, and lateral) axes as well as three orthogonal rotational (i.e., pitch, roll, and yaw) axes so as to provide a full six degrees freedom of motion to placement of the patient pod 200.
It will be understood that the patient can be positioned in any number of ways, including, but not limited to, automatic, semi-automatic (e.g., with a hand pendent), manual controlled with direct interface to the positioner controller, or full manual (e.g., releasing a brake and moving each device axis with a hand crank).
With reference to
A swivel joint 152 at the distal end 116 of the robotic arm 150 is capable of rotating any devices connected to its distal end in a clockwise or counterclockwise manner. The swivel joint 152 is typically interfaces with a positioner-pod connector 234, which in turn connects with the a patient pod 200. Robotic arm segment 162 and any distally located arm components are capable of being rotated about swivel joint 154. Robotic arm segment 164 and any distally located arm components are capable of being rotated about swivel joint 156. Robotic arm segment 166 and any distally located arm components are capable of being rotated about swivel joint 158. Robotic arm segment 168 and any distally located arm components are capable of being rotated about swivel joint 159. Robotic arm segment 170 and any distally located arm components are capable of being rotated about swivel joint 160.
With reference to
With reference to
The system 100 is under regulation and operator control through a control system that is generally patterned after the system used for the Loma Linda University Medical Center 200 MeV synchrotron facility. The control system provides an operator controllable system for controlling the rotational position of the gantry 102, as well as the translational and rotational position of the patient positioner 114. The control system provides timing pulses to the entire system 100.
In one embodiment, the control system comprises multiple distributed microprocessor-based systems networked together and to a workstation computer using a Local Area Network (LAN) Standard. The LAN is an Ethernet based protocol. The workstation performs the centralized coordination of beam requests from the treatment stations in the therapy system as well as programmed beam-energy control.
Additional details on the structure and operation of the radiation therapy systems can be found in commonly assigned applications—namely, U.S. Pat. No. 7,280,633, issued on Oct. 9, 2007, concurrently filed herewith, titled PATH PLANNING AND COLLISION AVOIDANCE FOR MOVEMENT OF INSTRUMENTS IN A RADIATION THERAPY ENVIRONMENT, and U.S. Pat. No. 7,199,382, issued on Apr. 3, 2007, concurrently filed herewith, titled PATIENT ALIGNMENT SYSTEM WITH EXTERNAL MEASUREMENT AND OBJECT COORDINATION FOR RADIATION THERAPY SYSTEM, the contents of each of which are hereby incorporated in their entirety into this disclosure by reference.
In accordance with the one embodiment described herein, there is provided a modular patient support system that generally comprises a modular patient pod and an immobilization device.
The pod 200, any components thereof, and any extensions or attachments thereto, are described herein with reference to the section of the pod 200 which interfaces with the patient positioner 114 via a positioner-pod connector 234. Any components, extensions, and attachments that are closer, along a visualized longitudinal axis of the pod 200, to the connector 234 are referred to herein as being proximal, while any components, extensions, and attachments located toward the opposite end of the pod are referred to herein as being distal.
The longitudinally extending shell structure 212 extends between a shell proximal edge 214 and a shell distal edge 216. The shell 212 has a transverse concave top surface 218 and a transverse concave bottom surface 220. The shell 212 transversely extends between a first upwardly-extending lateral edge 222 and a second upwardly-extending lateral edge 224.
With reference to
The patient can be positioned in the patient pod 200 in any number of positions. In one approach, where the patient is positioned in the pod 200 in a supine position with his head near the shell distal edge 216 and his feet near the shell proximal edge 214, the lateral edge 222 is on the patient's right-hand side while the lateral edge 224 is on the patient's left-hand side. In another approach, where the patient is positioned in the pod 200 in a prone position with his head near the shell distal edge 216 and his feet near the shell proximal edge 214, the lateral edge 222 is on the patient's left-hand side while the lateral edge 224 is on the patient's right-hand side. In yet another approach, where the patient is positioned in the pod 200 in a supine position with his feet near the shell distal edge 216 and his head near the shell proximal edge 214, the lateral edge 222 is on the patient's left-hand side while the lateral edge 224 is on the patient's right-hand side.
With reference to
In one method of use, involving treatment near the patient's head region, the patient is positioned with his head beyond shell edge 216 on a head rest extension 310 attached to track 228. In another method of use, involving treatment in the patient's lung region, the patient is positioned head-first (i.e., head near shell edge 216) with his shoulders inline with track 228 so that the radiation beam passes through the shell 212 and into the lung region. In yet another method of use, involving treatment in the patient's lung region, the patient is positioned head-first with his shoulders beyond the track 228 so that treatment occurs outside the shell 212.
As used herein, negative pitch refers generally to the lowering or dipping of the pod 200 distal end, while positive pitch refers generally to the raising of the pod 200 distal end. Negative roll refers generally to the counterclockwise rotation of the pod 200, while positive roll refers generally to the clockwise rotation of the pod 200. Negative yaw refers generally to the rotation of the pod 200 about Axis-6 to the left, while positive yaw refers generally to the rotation of the pod 200 about Axis-6 to the right.
The shell 212 is preferably sufficiently long and wide to receive most or all of the body of a human patient lying on it in any position, such as, for example, the supine or prone positions. The structural shell 212 length from Axis-6 to the distal edge 216 without attachments is typically in the range of about 75 cm to about 175 cm, often about 80 cm to about 125 cm, depending on the intended patient application specific size (e.g., pediatric) and/or gantry size. In one embodiment, the length of the shell 212 from Axis-6 to the distal edge 216 is on the order of 90 cm. As used herein, Axis-6 refers to the axis of the positioner 114 that extends vertically through the attachment at the final yaw axis (e.g., wrist) of the positioner 114 (e.g., in the embodiment shown in
The overall longitudinal length of the shell 212 (i.e., between shell proximal edge 214 and shell distal edge 216) is typically in the range of about 90 cm to about 235 cm, often about 95 cm to about 175 cm. In one embodiment, the overall longitudinal length of the shell 212 is about 106 cm. The outer diameter of the shell 212 is typically in the range of about 35 cm to about 65 cm, often about 35 to about 55 cm depending on the intended patient application specific size (e.g., pediatric, large patient, etc.) and/or available treatment energy. In one embodiment, the outer diameter of the shell 212 is about 46 cm.
In one embodiment, the shell 212 has a non-metallic (e.g., carbon fiber) composite construction that facilitates radiation beam treatments through the shell 212. Any number of imaging simulators known in the art (e.g., computed tomography imaging (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), cone beam imaging. etc.) can be used to account for the treat-through material of the shell 212. As used herein, the term “treat-through” refers generally to physical property of a material or surface that allows radiation beams to be irradiated through a surface, and thereby deliver prescribed radiation doses from a radiation source, through a surface, and into a targeted area within the patient on the other side of the surface. Treat-through properties are generally measured or quantified in terms of molecular equivalence of water. As used herein, the term “non-treat through” refers generally to the physical property of a material or surface that does not allow radiation beams to be irradiated through a surface. Areas of the shell 212 made of non-metallic materials are generally referred to as treat-through surfaces or zones.
As used herein, water equivalency refers generally to the effect of an absorbing material on proton beam range relative to water. With respect to the treat-through sections, zones, or surfaces described herein, water equivalency is measured with respect to radiation beams that are perpendicular to the penetrable surface.
In one embodiment, illustrated in
U.S. Provisional Application No. 60/583,063, filed Jun. 25, 2004, titled METHOD AND DEVICE FOR REGISTRATION AND IMMOBILIZATION, the disclosure of which is hereby incorporated in its entirety herein by reference, discloses some suitable materials from which the shell 212 can be constructed.
In one embodiment, the shell 212 is made from polyvinylchloride (PVC) or the like. In another embodiment, the shell 212 is made from fiberglass or the like. In still another embodiment, the shell 212 comprises any known suitable low density foam or the like.
In one embodiment, the shell 212 is constructed of composite skins comprising polyethylene fibers embedded in an epoxy resin and a low-density polystyrene foam (Styrofoam®) core. A list of some of the materials that can be used in manufacturing the shell 212 appears in Table I below.
In one embodiment, the carbon fiber composites, each woven ply of a lay-up is approximately 0.25 mm thick. In one embodiment, the composite lay-up is approximately 50% fiber and 50% resin by weight. In one embodiment, the fiber content of the composite is maximized while the resin content is minimized. In one embodiment, the shelf 212 of the pod 200 is made from the composite material Spectra, which is available from Honeywell Performance Fibers in Colonial Heights, Va.
In one embodiment, at least one of the extension tracks 226, 228 is made from any suitable metal known in the art, such as, for example, aluminum. The use of metal, however, results in non-treat through zones or areas. As such, the use of metal structures is generally limited in order to minimize non-treat through surfaces. In another embodiment, at least one of the tracks 226, 228 is made from a suitable non-metal material known in the art, such as, for example, a carbon composite.
The extension tracks 226, 228 are advantageously positioned at the shell edges 214 and 216 of the pod 200, thereby facilitating radiation treatment through the support shell 212 of the pod 200. The positioning of the extension tracks 226, 228 at the shell edges 214, 216 also facilitates the attachment of one or more pod extensions to the pod 200 as explained in further detail below.
In one embodiment, the extension tracks 226, 228 are rounded such that for certain treatment positions, the patient shall not experience pain or discomfort as the result of his contact with the track 226 or 228. The extension tracks 226, 228 preferably comprise interface extensions that are approximately flush with the inside surface 218 of the shell 212. In one embodiment, the maximum step or vertical distance between the inner surface 218 and the track interface extension is about 1 cm.
Extension tracks 226, 228 allow one or more pod extensions to be connected to the pod 200, and provide modularity to the overall design. For example, track 228 can accommodate multiple head extensions and allows for 2-pi head and neck treatments. The modularity of the pod components and optional pod extensions accommodate multiple patient positions within the pod 220, such as, for example, both head-first and feet-first treatment positions. The pod 200 also accommodates treatment positions where the patient lies on his back, side, stomach, or any variations thereof. It will be noted that actual position of the patient within the pod 200 will depend on various factors, such as, for example, the radiation treatment protocol, as determined by the physician and/or radiation physicist, and the physical characteristics of the patient.
With reference to
In one embodiment, the connector 236 (e.g., clamping plate) protrudes into the shell 212 with a height H of approximately 1.75 inches, extends longitudinally L along the shell 212 approximately 12 inches over the robot connection, and has a width W of approximately 11 inches. In another embodiment (not shown), the connector is integrated into the shell 212 and is flush to the contour of the inside surface of the shell 212.
It will be noted that the pod 200 and any mechanical device mounted thereto should be positioned to avoid collision with the positioner 114 during yaw treatment angles. The distance between the inside surface 218 of the shell 212 and the connector 234 is typically in the range of about 5 mm to about 35 mm, often about 12 mm to about 25 mm. In one embodiment, the distance between the inside surface 218 of the shell 212 and the connector 234 is about 19 mm.
The patient pod 200 can comprise one or more attachments, extensions, adapter plates, or the like, or combinations thereof (collectively, “pod attachments”). In one embodiment, shown in
With reference to
While these pod attachments can have treat-through surfaces that vary in water equivalent thickness, it is preferred that the treat-thought surfaces not vary in water equivalent thickness with a gradient greater than about 0.5 mm water equivalent thickness/mm along any transverse distance. The gradient limits will define design edge effects, thickness changes, and material transitions, as well as general manufacturing tolerances such as voids and material surface imperfections. In one embodiment, the attachments have water equivalencies of no more than about 2 cm. In one embodiment, the shell 212 has about a 25 mm wide non-treat through region due to the mounted attachment track 226 or 228. It will be noted that the certain embodiments where the tracks 226, 228 are made of metal, the tracks are non-treat through, whereas in certain other embodiments where the tracks 226, 228 are made of non-metal materials, such as, for example, carbon fiber, the tracks 226, 228 provide treat-through zones. As with the shell 212, certain pod attachments can comprise up to about a 25 mm wide non-treat through region due to the tracks 226, 228.
With reference to the embodiments shown in
With reference to
With reference to
With reference to
With reference to
With reference to
With reference to
With reference to
Any number of immobilization devices can be used with the patient pod 200. With reference to
In one approach, an expandable, liquid foaming agent known as ACMM foaming agent 325, available from the Soule Co., Inc., Lutz, Fla. or Smithers Medical Products, Inc., Akron, Ohio, is used to form the rigid foam cradle 350. In one approach, the foaming agent is painted onto the shell top surface 218. After the foaming agent is introduced within the shell, the patient is positioned within the shell where he lays motionless for approximately 15 minutes until the foaming agent has cooled to room temperature and the patient body mold 352 is formed.
The foam between the patient and the pod can be mechanically stabilized to prevent the foam from moving and displacing the patient between or during treatments. In one approach, the foam is placed inside a very thin plastic bag. In another approach, the pod is lined with a low-density foam sheet. In still another approach, a very thin, disposable, plastic shell is inserted into the pod before applying the foam chemicals. In yet another approach, there is no lining between the foam and pod; rather, the inner pod surface is made very smooth by the composite layers on a high quality aluminum mold. In still another approach, the inner surface of the pod is coated with Teflon or another nonreacting substance.
Other suitable immobilization devices that can be used with the patient pod 200, with or without any flat extensions, include, but are not limited to, bite blocks, face masks, vacuum bags, halos or cranial rings, localizer Z-frame boxes, triangular leg pillows, foam inserts, or the like, or combinations thereof. Bite block mouthpieces are preferably compatible with any existing MRI “Head Coils.” In one embodiment, the bite block frame preferably limits translational movement of any point in the treatable volume to no more than about 1.0 mm given the force of 30 pounds in any direction. In another embodiment, the bite block frame limits head rotations to less than or equal to about one-degree in any direction under a force of about 30 pounds in any direction. In one embodiment, the bite block frame mounts to the shell 212 and/or any pod attachments via an existing vacuum system providing approximately 9 psi.
With respect to the various pod attachments described above, the weight of any of the pod attachments preferably does not exceed about 30 pounds in weight, thereby making it easier for an individual to carry and install the pod attachment to the pod shell 212. Pod attachments mounted on the side near Axis-6 are preferably angled along the robotic arm or positioner to eliminate injury or collision.
In one embodiment, the pod 200 is capable of supporting a 400 pound distributed patient load (not including any immobilization devices) with the patient center of gravity not to exceed 37 inches from Axis-6. The pod 200 is preferably capable of supporting a 300 pound end load (with or without extensions) to accommodate an individual seated on the cantilevered end 216. In one embodiment, the pod 200 is capable of supporting a patient load of 300 lbf, an immobilization load of 50 lbf, and a 200 lbf longitudinal load located on the extensions.
In one embodiment, the pod 200 is preferably capable of supporting a water phantom load of 275 pounds (125 kg) at the proximal extension track 226.
In one embodiment, the pod 200 is capable of supporting an immobilization and patient load of up to approximately 150 pounds located on the attachments with a deflection of no more than 2 mm. Extensions are preferably capable of supporting a 300 pound load at the end in the event a person were to sit on the extension, thereby resulting in a pod with extension that is not overly flexible.
With continued reference to
The vertical deflection of the patient pod 200 at the distal, cantilevered end (with or without extensions) due to a 300 pound patient distributed load and 50 pound immobilization load is preferably less than about 4 mm. The lateral deflection of the pod 200 (with or without extensions) due to a patient lateral load of 100 pounds is preferably less than about 0.5 mm. It will be noted that these types of vertical and lateral deflections can be compensated for during treatment by using an external measurement system that corrects inherent mechanical errors.
All table constituent materials and components preferably withstand an average daily radiation dose of approximately 9,000 rads, 5 days per week, 52 weeks per year, over a 20 year lifetime. All hardware and components preferably operate normally in the temperature environment of 40-95 degrees F. with a relative humidity of 25-78%.
The treat-through surfaces of the pod 200 preferably do not vary in thickness with a gradient greater than about 0.5 mm water equivalent thickness per mm along any transverse distance. The edges of treat-through areas of the pod 200 are preferably less than about 0.5 mm water equivalent thickness. In one embodiment, the treat-through thickness of the pod 200 preferably has a water equivalency of less than approximately 2 cm.
Components of the pod 200 positioned between the patient and the radiographic image receptor preferably have an aluminum equivalence less than or equal to about 5 mm per FDA CFR part 1020.
With continued reference to
The pod attachments preferably have an aluminum equivalence of about 5 mm per FDA CFR Part 1020 (Compliance determined by x-ray measurements made at a potential of 100 kilovolts peak and with an x-ray beam that has a HVL of 2.7 mm of aluminum). As used herein, aluminum equivalency refers to the thickness of aluminum (type 1100 alloy) affording the same radiographic attenuation, under same specified conditions, as the material in question. It will be noted that the modular patient support system 199 is preferably capable of accommodating a 65 cm×60 cm×60 cm water phantom at the robot end.
In one embodiment, the radiation treatment system 100 comprises an external measurement or vision system, which further comprises vision system markers. The vision system markers are preferably mounted to the non-treat through areas, such as, for example, tracks 226, 228 made of metal.
In accordance with one embodiment described herein, there is provided a patient pod with a tapered edge configuration that reduces edge effects associated with abrupt changes in the water equivalency in the radiation beam path.
For certain radiation treatment protocols, radiation beams of a prescribed intensity are delivered from lateral positions. In certain instances, for example, where the radiation beam is delivered from a lateral position that is well above patient pod, the radiation beam does not have to be delivered through the patient pod. In another scenario, where the radiation beam is delivered from a lateral position that is well below the patient pod, the radiation beam can pass through a pod shell surface of uniform density or water equivalency. There are situations, however, where the radiation beam traverses one or both of the lateral edges (e.g., lateral edge 222 or 224 of the pod shell 212 depicted in
Sections of the lateral edges of the patient pod can be tapered to reduce or minimize the edge effects. With reference to
With reference to
The lateral edges of the pod are relatively thin, thereby minimally perturbing any therapeutic proton beams passing through or near any of the lateral edges.
The low-density rail 299 covers tapered edge 243, and thereby protects the patient and radiation treatment providers from the upper edge 248 which tends to be a sharp edge. With reference to exemplary shell lateral edge 222 illustrated in
The rail 299 preferably comprises a low-density material, such as, for example, epoxy with microspheres, extruded or molded plastics (nylon, urethane, etc.), rubber, or the like, or combinations thereof. In one embodiment, the rail 299 maintains the 0.5 mm/mm water equivalent gradient of the shell 212.
In one embodiment, the rail 299 is removably secured to the shell tapered edge 243 via any attachment mechanism known in the art, such as, for example, an interlocking receiver molded into the shell 212 for positive locating and holding of the rail 299. In another embodiment, the rail 299 simply sits the tapered edge 243 without the aid of any attachment mechanisms. In yet another embodiment, the rail 299 is permanently secured to the tapered edge 243 using any known suitable attachment mechanism, such as, for example, epoxy with micro-spheres. Patient safety and comfort are preferably integrated with each embodiment. Several transitions, methods, and materials can be used to achieve specified gradient, level of safety and patient comfort, such as, for example, replaceable handrails or pliable edges.
The aimable volume will generally depend on the orientation of the patient pod 200 and the patient positioner 114 that interfaces with the patient pod 200 along the orthogonal translational and rotational axes.
It will be understood that the invention described herein, and the component parts thereof, can be sued in any number of combination of treatment systems, including, but not limited to, proton treatment, conventional radiation treatment, and imaging systems (e.g., CT, PET, MRI, cone beam, etc.).
While the present invention has been illustrated and described with particularity in terms of preferred embodiments, it should be understood that no limitation of the scope of the invention is intended thereby. Features of any of the foregoing devices and methods may be substituted or added into the others, as will be apparent to those of skill in the art. The scope of the invention is defined only by the claims appended hereto. It should also be understood that variations of the particular embodiments described herein incorporating the principles of the present invention will occur to those of ordinary skill in the art and yet be within the scope of the appended claims.
This application is a continuation application of U.S. application Ser. No. 10/917,022, filed Aug. 12, 2004 which claims priority to U.S. Provisional Application No. 60/494,699, filed Aug. 12, 2003, titled PRECISION PATIENT ALIGNMENT AND BEAM THERAPY SYSTEM, and to U.S. Provisional Application No. 60/579,095, filed Jun. 10, 2004, titled PRECISION PATIENT ALIGNMENT AND BEAM THERAPY SYSTEM, the contents of each of which are hereby incorporated in their entirety into this disclosure by reference.
This invention was made with United States Government support under grants DAMD17-99-1-9477 and DAMD17-02-1-0205 awarded by the Department of Defense. The Government has certain rights in the invention.
Number | Name | Date | Kind |
---|---|---|---|
2469084 | Schenker | May 1949 | A |
2675564 | Hughes | Apr 1954 | A |
3397411 | Rossi | Aug 1968 | A |
3449570 | Kok | Jun 1969 | A |
3545739 | D'Avignon | Dec 1970 | A |
3556455 | Storm | Jan 1971 | A |
3604931 | Kastner et al. | Sep 1971 | A |
3640787 | Heller | Feb 1972 | A |
3689949 | Weinstein et al. | Sep 1972 | A |
3745998 | Rose | Jul 1973 | A |
3762404 | Sakita | Oct 1973 | A |
3778049 | Viamonte, Jr. | Dec 1973 | A |
3783251 | Pavkovich | Jan 1974 | A |
3848132 | Foderaro | Nov 1974 | A |
3851644 | Slagle | Dec 1974 | A |
3852610 | McIntyre | Dec 1974 | A |
3885258 | Regan | May 1975 | A |
3893198 | Blair | Jul 1975 | A |
3897345 | Foster | Jul 1975 | A |
3897777 | Morrison | Aug 1975 | A |
3901588 | Longhenry | Aug 1975 | A |
3905054 | Windsor et al. | Sep 1975 | A |
3942012 | Boux | Mar 1976 | A |
3947686 | Cooper et al. | Mar 1976 | A |
3986697 | Amor, Jr. et al. | Oct 1976 | A |
4034224 | Heavens et al. | Jul 1977 | A |
4064401 | Marden | Dec 1977 | A |
4069457 | Martin et al. | Jan 1978 | A |
4095114 | Taumann | Jun 1978 | A |
4112306 | Nunan | Sep 1978 | A |
4146793 | Bergstrom et al. | Mar 1979 | A |
4190772 | Dinwiddie et al. | Feb 1980 | A |
4206355 | Boux | Jun 1980 | A |
4230129 | LeVeen | Oct 1980 | A |
4252594 | Cooper | Feb 1981 | A |
4256112 | Kopf et al. | Mar 1981 | A |
4262204 | Mirabella | Apr 1981 | A |
4269512 | Nosler | May 1981 | A |
4287425 | Elliott, Jr. | Sep 1981 | A |
4327046 | Davis et al. | Apr 1982 | A |
4347213 | Rogers, Jr. | Aug 1982 | A |
4378813 | Lovelace et al. | Apr 1983 | A |
4392239 | Wilkens | Jul 1983 | A |
4400820 | O'Dell et al. | Aug 1983 | A |
4442352 | Brahme | Apr 1984 | A |
4450122 | Gallina | May 1984 | A |
4484571 | Velasquez | Nov 1984 | A |
4504050 | Osborne | Mar 1985 | A |
4552508 | Reid | Nov 1985 | A |
4578757 | Stark | Mar 1986 | A |
4591341 | Andrews | May 1986 | A |
4616814 | Harwood-Nash et al. | Oct 1986 | A |
4666304 | Davies | May 1987 | A |
4671284 | Wilson et al. | Jun 1987 | A |
4672212 | Brahme | Jun 1987 | A |
4682818 | Morell | Jul 1987 | A |
4688780 | Hanz | Aug 1987 | A |
4705955 | Mileikowsky | Nov 1987 | A |
4752064 | Voss | Jun 1988 | A |
4779858 | Saussereau | Oct 1988 | A |
4789930 | Sones et al. | Dec 1988 | A |
4796613 | Heumann et al. | Jan 1989 | A |
4812658 | Koehler | Mar 1989 | A |
4815448 | Mills | Mar 1989 | A |
4819257 | Grasser et al. | Apr 1989 | A |
4841965 | Jacobs | Jun 1989 | A |
4848340 | Bille et al. | Jul 1989 | A |
4870287 | Cole et al. | Sep 1989 | A |
4905267 | Miller et al. | Feb 1990 | A |
4917344 | Prechter et al. | Apr 1990 | A |
4926457 | Poehner et al. | May 1990 | A |
4979519 | Chavarria et al. | Dec 1990 | A |
5014290 | Moore et al. | May 1991 | A |
5017789 | Young et al. | May 1991 | A |
5037374 | Carol | Aug 1991 | A |
5039057 | Prechter et al. | Aug 1991 | A |
5039867 | Nishihara et al. | Aug 1991 | A |
5046708 | Schaefer | Sep 1991 | A |
5048071 | Van Steenburg | Sep 1991 | A |
5049147 | Danon | Sep 1991 | A |
5054049 | Manabe | Oct 1991 | A |
5079426 | Antonuk et al. | Jan 1992 | A |
5081665 | Kostich | Jan 1992 | A |
5090047 | Angotti et al. | Feb 1992 | A |
5094241 | Allen | Mar 1992 | A |
5107839 | Houdek et al. | Apr 1992 | A |
5117829 | Miller et al. | Jun 1992 | A |
5156166 | Sebring | Oct 1992 | A |
5168514 | Horton, Jr. et al. | Dec 1992 | A |
5207688 | Carol | May 1993 | A |
5240218 | Dye | Aug 1993 | A |
5242455 | Skeens et al. | Sep 1993 | A |
5269305 | Corol | Dec 1993 | A |
5274864 | Morgan | Jan 1994 | A |
5276927 | Day | Jan 1994 | A |
5278886 | Ohgushi et al. | Jan 1994 | A |
5281232 | Hamilton et al. | Jan 1994 | A |
5287576 | Fraser | Feb 1994 | A |
5343048 | Pastyr | Aug 1994 | A |
5361765 | Herlihy et al. | Nov 1994 | A |
5370117 | McLaurin, Jr. | Dec 1994 | A |
5370118 | Vij et al. | Dec 1994 | A |
5380336 | Misko et al. | Jan 1995 | A |
5382914 | Hamm et al. | Jan 1995 | A |
5388580 | Sullivan et al. | Feb 1995 | A |
5402463 | Umetani et al. | Mar 1995 | A |
5427097 | Depp | Jun 1995 | A |
5446548 | Gerig et al. | Aug 1995 | A |
5454993 | Kostich | Oct 1995 | A |
5464411 | Schulte et al. | Nov 1995 | A |
5485833 | Dietz | Jan 1996 | A |
5511549 | Legg et al. | Apr 1996 | A |
5531229 | Dean et al. | Jul 1996 | A |
5538494 | Matsuda | Jul 1996 | A |
5549616 | Schulte | Aug 1996 | A |
5566681 | Manwaring et al. | Oct 1996 | A |
5570409 | Yamaguchi et al. | Oct 1996 | A |
5577707 | Brida | Nov 1996 | A |
5588430 | Bova et al. | Dec 1996 | A |
5595191 | Kirk | Jan 1997 | A |
5596619 | Carol | Jan 1997 | A |
5602892 | Llacer | Feb 1997 | A |
5622187 | Carol | Apr 1997 | A |
5675851 | Feathers | Oct 1997 | A |
5676673 | Ferre et al. | Oct 1997 | A |
5727554 | Kalend et al. | Mar 1998 | A |
5745545 | Hughes | Apr 1998 | A |
5751781 | Brown et al. | May 1998 | A |
5771512 | Kurakake et al. | Jun 1998 | A |
5775337 | Hauger et al. | Jul 1998 | A |
5778047 | Mansfield et al. | Jul 1998 | A |
5792147 | Evans et al. | Aug 1998 | A |
5797924 | Schulte et al. | Aug 1998 | A |
5800352 | Ferre et al. | Sep 1998 | A |
5806116 | Oliver et al. | Sep 1998 | A |
5820444 | McGaughey | Oct 1998 | A |
5820553 | Hughes | Oct 1998 | A |
5823192 | Kalend et al. | Oct 1998 | A |
5825845 | Blair et al. | Oct 1998 | A |
5832550 | Hauger et al. | Nov 1998 | A |
5847403 | Hughes et al. | Dec 1998 | A |
5848449 | Hauger et al. | Dec 1998 | A |
5851182 | Sahadevan | Dec 1998 | A |
5865832 | Knopp et al. | Feb 1999 | A |
5895926 | Britton et al. | Apr 1999 | A |
5911655 | Brenneisen | Jun 1999 | A |
5947981 | Cosman | Sep 1999 | A |
5983424 | Näslund | Nov 1999 | A |
6003174 | Kantrowitz et al. | Dec 1999 | A |
6023694 | Kouchi et al. | Feb 2000 | A |
6026392 | Kouchi et al. | Feb 2000 | A |
6085227 | Edlund et al. | Jul 2000 | A |
6094760 | Nonaka et al. | Aug 2000 | A |
6104779 | Shepherd et al. | Aug 2000 | A |
6118848 | Reiffel | Sep 2000 | A |
6161237 | Tang et al. | Dec 2000 | A |
6178430 | Cohen et al. | Jan 2001 | B1 |
6195578 | Distler et al. | Feb 2001 | B1 |
6240161 | Siochi | May 2001 | B1 |
6275564 | Ein-Gal | Aug 2001 | B1 |
6279579 | Riaziat et al. | Aug 2001 | B1 |
6282739 | Livingston | Sep 2001 | B1 |
6308353 | Van Steenburg | Oct 2001 | B1 |
6316776 | Hiramoto et al. | Nov 2001 | B1 |
6325758 | Carol et al. | Dec 2001 | B1 |
6345114 | Mackie et al. | Feb 2002 | B1 |
6375355 | Fortin | Apr 2002 | B1 |
6376846 | Livingston | Apr 2002 | B2 |
6385286 | Fitchard et al. | May 2002 | B1 |
6405072 | Cosman | Jun 2002 | B1 |
6437513 | Selzer et al. | Aug 2002 | B1 |
6445766 | Whitham | Sep 2002 | B1 |
6446286 | Karmalawy | Sep 2002 | B1 |
6452999 | Maida | Sep 2002 | B1 |
6462490 | Matsuda et al. | Oct 2002 | B1 |
6462553 | Badura | Oct 2002 | B1 |
6466813 | Shukla et al. | Oct 2002 | B1 |
6473490 | Siochi | Oct 2002 | B1 |
6476403 | Dolinskii et al. | Nov 2002 | B1 |
6509573 | Badura et al. | Jan 2003 | B1 |
6565577 | Cosman | May 2003 | B2 |
6597005 | Badura et al. | Jul 2003 | B1 |
6598275 | Kolody et al. | Jul 2003 | B1 |
6600164 | Badura et al. | Jul 2003 | B1 |
6614038 | Brand et al. | Sep 2003 | B1 |
6621889 | Mostafavi | Sep 2003 | B1 |
6639234 | Badura et al. | Oct 2003 | B1 |
6650930 | Ding | Nov 2003 | B2 |
6662036 | Cosman | Dec 2003 | B2 |
6670618 | Hartmann et al. | Dec 2003 | B1 |
6677597 | Haberer et al. | Jan 2004 | B1 |
6683318 | Haberer et al. | Jan 2004 | B1 |
6690965 | Riaziat et al. | Feb 2004 | B1 |
6693283 | Eickhoff et al. | Feb 2004 | B2 |
6698045 | Coppens et al. | Mar 2004 | B1 |
6704957 | Rhodes | Mar 2004 | B2 |
6710362 | Kraft et al. | Mar 2004 | B2 |
6725078 | Bucholz et al. | Apr 2004 | B2 |
6730921 | Kraft | May 2004 | B2 |
6731970 | Schlossbauer et al. | May 2004 | B2 |
6736831 | Hartmann et al. | May 2004 | B1 |
6745072 | Badura et al. | Jun 2004 | B1 |
6754299 | Patch | Jun 2004 | B2 |
6757355 | Siochi | Jun 2004 | B1 |
6769806 | Moyers | Aug 2004 | B2 |
6774383 | Norimine et al. | Aug 2004 | B2 |
6777700 | Yanagisawa et al. | Aug 2004 | B2 |
6780149 | Schulte | Aug 2004 | B1 |
6792078 | Kato et al. | Sep 2004 | B2 |
6795523 | Steinberg | Sep 2004 | B2 |
6799068 | Hartmann et al. | Sep 2004 | B1 |
6803591 | Muramatsu et al. | Oct 2004 | B2 |
6804548 | Takahashi et al. | Oct 2004 | B2 |
6809325 | Dahl et al. | Oct 2004 | B2 |
6813788 | Dinkler et al. | Nov 2004 | B2 |
6814694 | Pedroni | Nov 2004 | B1 |
6839404 | Clark et al. | Jan 2005 | B2 |
6855942 | Bechthold et al. | Feb 2005 | B2 |
6859741 | Haberer et al. | Feb 2005 | B2 |
6891177 | Kraft et al. | May 2005 | B1 |
6977987 | Yamashita et al. | Dec 2005 | B2 |
7011447 | Moyers | Mar 2006 | B2 |
7076821 | de Mooy | Jul 2006 | B2 |
7120223 | Nafstadius | Oct 2006 | B2 |
7142634 | Engler et al. | Nov 2006 | B2 |
7154108 | Tadokoro et al. | Dec 2006 | B2 |
7154991 | Earnst et al. | Dec 2006 | B2 |
7173265 | Miller et al. | Feb 2007 | B2 |
7199382 | Rigney et al. | Apr 2007 | B2 |
7280633 | Cheng et al. | Oct 2007 | B2 |
7301162 | Matsuda et al. | Nov 2007 | B2 |
7331713 | Moyers | Feb 2008 | B2 |
7348579 | Pedroni | Mar 2008 | B2 |
7372053 | Yamashita et al. | May 2008 | B2 |
7398309 | Baumann et al. | Jul 2008 | B2 |
7446328 | Rigney et al. | Nov 2008 | B2 |
20020027969 | Maida | Mar 2002 | A1 |
20020032378 | Henderson et al. | Mar 2002 | A1 |
20020051513 | Pugachev et al. | May 2002 | A1 |
20020065461 | Cosman | May 2002 | A1 |
20020077545 | Takahashi et al. | Jun 2002 | A1 |
20020095730 | Al-Kassim et al. | Jul 2002 | A1 |
20020120986 | Erbel et al. | Sep 2002 | A1 |
20020188194 | Cosman | Dec 2002 | A1 |
20020193685 | Mate et al. | Dec 2002 | A1 |
20030007601 | Jaffray et al. | Jan 2003 | A1 |
20030031301 | Longton et al. | Feb 2003 | A1 |
20030086527 | Speiser et al. | May 2003 | A1 |
20030095625 | Steinberg | May 2003 | A1 |
20030164459 | Schardt et al. | Sep 2003 | A1 |
20030183779 | Norimine et al. | Oct 2003 | A1 |
20040013414 | Karger et al. | Jan 2004 | A1 |
20040028188 | Amann et al. | Feb 2004 | A1 |
20040034438 | Uematsu | Feb 2004 | A1 |
20040034932 | Zacharopoulos et al. | Feb 2004 | A1 |
20040042583 | Wackerle et al. | Mar 2004 | A1 |
20040082856 | Marmarelis | Apr 2004 | A1 |
20040098445 | Baumann et al. | May 2004 | A1 |
20040123388 | Coppens et al. | Jul 2004 | A1 |
20040136495 | Carlsson et al. | Jul 2004 | A1 |
20040155206 | Marchand et al. | Aug 2004 | A1 |
20040158145 | Ghelmansarai et al. | Aug 2004 | A1 |
20040174958 | Moriyama et al. | Sep 2004 | A1 |
20040184579 | Mihara et al. | Sep 2004 | A1 |
20040184583 | Nagamine et al. | Sep 2004 | A1 |
20050116175 | Haberer | Jun 2005 | A1 |
20050161618 | Pedroni | Jul 2005 | A1 |
20050281374 | Cheng et al. | Dec 2005 | A1 |
20060002511 | Miller et al. | Jan 2006 | A1 |
20060017022 | Rigney et al. | Jan 2006 | A1 |
20060183960 | Sioshansi et al. | Aug 2006 | A1 |
20070039621 | Moyers | Feb 2007 | A1 |
20070093100 | Sommer | Apr 2007 | A1 |
20070158592 | Hiramoto et al. | Jul 2007 | A1 |
20070164230 | Rigney et al. | Jul 2007 | A1 |
20070262269 | Trbojevic | Nov 2007 | A1 |
20080005643 | Park et al. | Jan 2008 | A1 |
20080031414 | Coppens | Feb 2008 | A1 |
20080042076 | Miller et al. | Feb 2008 | A1 |
20080056434 | Grozinger et al. | Mar 2008 | A1 |
20080187097 | Cheng et al. | Aug 2008 | A1 |
20080189859 | Sloan et al. | Aug 2008 | A1 |
20080191142 | Pedroni | Aug 2008 | A1 |
20080192892 | Dilmanian et al. | Aug 2008 | A1 |
20080292053 | Marash et al. | Nov 2008 | A1 |
20080317216 | Lifshitz et al. | Dec 2008 | A1 |
20090067577 | Rigney et al. | Mar 2009 | A1 |
20090154645 | Lifshitz et al. | Jun 2009 | A1 |
20090202045 | Guertin et al. | Aug 2009 | A1 |
20090217456 | Lempen et al. | Sep 2009 | A1 |
Number | Date | Country |
---|---|---|
2513896 | Oct 1975 | DE |
2833800 | Dec 1979 | DE |
4418216 | Nov 1995 | DE |
19612091 | Mar 1997 | DE |
247449 | Dec 1987 | EP |
283082 | Sep 1988 | EP |
480035 | Apr 1992 | EP |
809525 | Dec 1997 | EP |
986070 | Mar 2000 | EP |
986071 | Mar 2000 | EP |
1064881 | Jan 2001 | EP |
1 454 653 | Sep 2004 | EP |
1454653 | Sep 2004 | EP |
1584353 | Oct 2005 | EP |
1709994 | Oct 2006 | EP |
1792595 | Jun 2007 | EP |
1795229 | Jun 2007 | EP |
1900392 | Mar 2008 | EP |
1935453 | Jun 2008 | EP |
2701391 | Aug 1994 | FR |
0870225 | Jun 1961 | GB |
1362678 | Aug 1974 | GB |
2213066 | Aug 1989 | GB |
2254691 | Oct 1992 | GB |
61194400 | Aug 1986 | JP |
2003527763 | Sep 2003 | JP |
7309246 | Oct 1974 | NL |
WO 8801848 | Mar 1988 | WO |
WO 9011721 | Oct 1990 | WO |
WO 9011723 | Oct 1990 | WO |
WO 9910137 | Mar 1999 | WO |
WO 0016175 | Mar 2000 | WO |
WO 0059575 | Oct 2000 | WO |
WO 0100276 | Jan 2001 | WO |
WO 0189625 | Nov 2001 | WO |
WO 0263638 | Feb 2002 | WO |
WO 03039212 | May 2003 | WO |
WO 03053520 | Jul 2003 | WO |
WO 03076016 | Sep 2003 | WO |
WO 2004026401 | Apr 2004 | WO |
WO 2004032781 | Apr 2004 | WO |
WO 2005018734 | Mar 2005 | WO |
WO 2005018735 | Mar 2005 | WO |
WO 2005037167 | Apr 2005 | WO |
WO 2005037167 | Apr 2005 | WO |
WO 2005102453 | Nov 2005 | WO |
WO 2006060886 | Jun 2006 | WO |
WO 2006076545 | Jul 2006 | WO |
WO 2006094533 | Sep 2006 | WO |
WO 2007054140 | May 2007 | WO |
WO 2007061426 | May 2007 | WO |
WO 2007062788 | Jun 2007 | WO |
WO 2007068066 | Jun 2007 | WO |
WO2007127970 | Nov 2007 | WO |
WO 2008051358 | May 2008 | WO |
WO 2008064271 | May 2008 | WO |
WO 2008081480 | Jul 2008 | WO |
WO2008142695 | Nov 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20080042076 A1 | Feb 2008 | US |
Number | Date | Country | |
---|---|---|---|
60494699 | Aug 2003 | US | |
60579095 | Jun 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10917022 | Aug 2004 | US |
Child | 11671922 | US |